<p>禮來公司（NYSE:LLY - 獲取免費報告）的股票在週四上漲了 1%。該股最高交易價格為$787.00，最後交易價格為$779.77。在交易過程中，共交易了 538,739 股，較平均交易量 3,211,798 股下降了 83%。該股此前收盤價為$772.00。</p>
<p>獲取 <strong>禮來公司</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>輝瑞：購買該股票的四個理由</li>
</ul>
<p>幾家研究公司最近對 LLY 進行了評估。美國銀行在 12 月 10 日的研究報告中重申了對禮來公司的 “買入” 評級，並給出了$997.00 的目標價格。Truist Financial 在 10 月 10 日的報告中將禮來公司的目標價格從$1,000.00 上調至$1,033.00，並給予該公司 “買入” 評級。巴克萊在 10 月 31 日的研究報告中將禮來公司的目標價格從$1,025.00 下調至$975.00，並對該公司設定了 “增持” 評級。摩根大通在 9 月 13 日的報告中將禮來公司的目標價格從$1,050.00 上調至$1,100.00，並給予該股票 “增持” 評級。最後，Redburn Atlantic 在 11 月 4 日的研究報告中將禮來公司升級為 “持有” 評級。四位投資分析師對該股票給予了持有評級，十八位分析師則給予了買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價格為$1,002.22。</p>
<p><strong>查看我們最新的 LLY 股票報告</strong></p>
<h2>禮來公司股票上漲 0.2%</h2>
<ul>
<li>三隻大牌股票剛剛宣佈了大幅分紅增加</li>
</ul>
<p>該股市值為 7341.6 億美元，市盈率為 83.61，市盈增長比率為 2.99，貝塔值為 0.41。該公司的 50 日移動平均價格為$798.30，200 日移動平均價格為$865.06。公司的債務與股本比率為 2.03，流動比率為 1.27，速動比率為 0.97。</p>
<p>禮來公司（NYSE:LLY - 獲取免費報告）最近在 10 月 30 日發佈了季度財報。該公司報告每股收益為$1.18，低於分析師一致預期的$1.52，差額為 ($0.34)。該公司季度收入為 114.4 億美元，而分析師預期為 120.9 億美元。禮來公司的股本回報率為 71.08%，淨利潤率為 20.48%。該公司的季度收入較去年同期增長了 20.4%。去年同期，該公司每股收益為$0.10。賣方分析師預測，禮來公司在當前財政年度的每股收益將達到$13.18。</p>
<h2>禮來公司增加分紅</h2>
<ul>
<li>諾和諾德：GLP-1 銷售的新動力即將到來</li>
</ul>
<p>該公司最近還披露了季度分紅，將於 3 月 10 日支付。2 月 14 日的股東將獲得每股$1.50 的分紅。這比禮來公司之前的季度分紅$1.30 有所增加。除息日為 2 月 14 日。這代表着每年$6.00 的分紅和 0.78% 的收益率。禮來公司的分紅支付比率目前為 64.86%。</p>
<p>禮來公司宣佈其董事會已於 12 月 9 日啓動了一項股票回購計劃，允許公司回購 150 億美元的股票。該回購授權允許公司通過公開市場購買最多 2% 的股票。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
<h2>禮來公司的內部交易</h2>
<p>在其他禮來公司的新聞中，首席會計官 Donald A. Zakrowski 在 11 月 8 日的交易中出售了 900 股禮來公司的股票。該股票以平均價格$803.38 出售，總交易額為$723,042.00。交易完成後，首席會計官現在持有該公司 5,480 股股票，價值約$4,402,522.40。此次交易使其持股減少了 14.11%。該交易已在向證券交易委員會提交的文件中披露，文件可通過 SEC 網站訪問。目前，內部人士持有該股票的 0.13%。</p>
<h2>機構資金流入和流出</h2>
<p>最近，一些大型投資者調整了他們在禮來公司的持股。國際資產投資管理公司在第三季度將其在禮來公司的股份增加了 87,091.7%。國際資產投資管理公司現在擁有 12,463,182 股該公司的股票，價值 11,041,631,000 美元，此前在上個季度又增持了 12,448,888 股。Pathway Financial Advisers LLC 在第三季度將其在禮來公司的股份增加了 92,759.9%。Pathway Financial Advisers LLC 現在擁有 1,022,388 股該公司的股票，價值 905,774,000 美元，此前在上個季度又增持了 1,021,287 股。Wulff Hansen &amp; CO.在第二季度將其在禮來公司的股份增加了 90,438.0%。Wulff Hansen &amp; CO.現在擁有 937,068 股該公司的股票，價值 848,403,000 美元，此前在上個季度又增持了 936,033 股。Integrated Investment Consultants LLC 在第三季度將其在禮來公司的股份增加了 37,140.7%。Integrated Investment Consultants LLC 現在擁有 694,167 股該公司的股票，價值 614,990,000 美元，此前在上個季度又增持了 692,303 股。最後，Comerica Bank 在第二季度將其在禮來公司的持股增加了 71.6%。Comerica Bank 現在擁有 1,512,983 股該公司的股票，價值 1,369,825,000 美元，此前在上個季度又增持了 631,312 股。機構投資者持有該公司 82.53% 的股份。</p>
<h2>禮來公司公司簡介</h2>
<p>(獲取免費報告)</p>
<p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比禮來公司更好的股票</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>3 家傳統科技公司重新崛起為 AI 領導者</li>
<li>什麼是支撐位？</li>
<li>分析師最喜歡的網絡安全股票：3 個頂級推薦</li>
<li>3 只提供優厚股息收益的天然氣股票</li>
<li>分析師看好：3 家科技巨頭的目標價被上調</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<p>→ 我們在 2021 年推薦了 Palantir，現在我們推薦這個...（來自 Behind the Markets）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTExNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTExNQ"/></p>
<h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
<p>在考慮禮來公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而禮來公司並不在名單上。</p>
<p>雖然禮來公司目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

禮來

<p>禮來公司（NYSE: LLY）股價上漲 1%，至 779.77 美元，交易量顯著低於平均水平。分析師對其前景持積極態度，普遍評級為 “適度買入”，平均目標價為 1,002.22 美元。該公司報告季度每股收益為 1.18 美元，未達到預期，但收入同比增長 20.4%。禮來宣佈每股股息增加至 1.50 美元，並啓動 150 億美元的股票回購計劃，顯示出對其股票價值的信心。近期的內部交易和機構投資反映出對該公司的持續關注</p>

<p>Shares of Eli Lilly and Company (NYSE:LLY - Get Free Report) shot up 1% on Thursday . The stock traded as high as $787.00 and last traded at $779.77. 538,739 shares were traded during trading, a decline of 83% from the average session volume of 3,211,798 shares. The stock had previously closed at $772.00.</p>
<div class="lb-trans"><p>禮來公司（NYSE:LLY - 獲取免費報告）的股票在週四上漲了 1%。該股最高交易價格為$787.00，最後交易價格為$779.77。在交易過程中，共交易了 538,739 股，較平均交易量 3,211,798 股下降了 83%。該股此前收盤價為$772.00。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>禮來公司</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Pfizer: 4 Reasons to Buy This Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>輝瑞：購買該股票的四個理由</li>
</ul>
</div><p>Several research firms recently weighed in on LLY. Bank of America reaffirmed a &#34;buy&#34; rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, October 10th. Barclays dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an &#34;overweight&#34; rating for the company in a research note on Thursday, October 31st. JPMorgan Chase &amp; Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, September 13th. Finally, Redburn Atlantic upgraded Eli Lilly and Company to a &#34;hold&#34; rating in a research report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $1,002.22.</p>
<div class="lb-trans"><p>幾家研究公司最近對 LLY 進行了評估。美國銀行在 12 月 10 日的研究報告中重申了對禮來公司的 “買入” 評級，並給出了$997.00 的目標價格。Truist Financial 在 10 月 10 日的報告中將禮來公司的目標價格從$1,000.00 上調至$1,033.00，並給予該公司 “買入” 評級。巴克萊在 10 月 31 日的研究報告中將禮來公司的目標價格從$1,025.00 下調至$975.00，並對該公司設定了 “增持” 評級。摩根大通在 9 月 13 日的報告中將禮來公司的目標價格從$1,050.00 上調至$1,100.00，並給予該股票 “增持” 評級。最後，Redburn Atlantic 在 11 月 4 日的研究報告中將禮來公司升級為 “持有” 評級。四位投資分析師對該股票給予了持有評級，十八位分析師則給予了買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價格為$1,002.22。</p>
</div><p><strong>Check Out Our Latest Stock Report on LLY</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 LLY 股票報告</strong></p>
</div><h2>Eli Lilly and Company Stock Up 0.2 %</h2>
<div class="lb-trans"><h2>禮來公司股票上漲 0.2%</h2>
</div><ul>
<li>3 Big-Name Stocks Just Announced Big-Time Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>三隻大牌股票剛剛宣佈了大幅分紅增加</li>
</ul>
</div><p>The stock has a market cap of $734.16 billion, a price-to-earnings ratio of 83.61, a price-to-earnings-growth ratio of 2.99 and a beta of 0.41. The firm's fifty day moving average price is $798.30 and its two-hundred day moving average price is $865.06. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.</p>
<div class="lb-trans"><p>該股市值為 7341.6 億美元，市盈率為 83.61，市盈增長比率為 2.99，貝塔值為 0.41。該公司的 50 日移動平均價格為$798.30，200 日移動平均價格為$865.06。公司的債務與股本比率為 2.03，流動比率為 1.27，速動比率為 0.97。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm's quarterly revenue was up 20.4% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. Sell-side analysts forecast that Eli Lilly and Company will post 13.18 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>禮來公司（NYSE:LLY - 獲取免費報告）最近在 10 月 30 日發佈了季度財報。該公司報告每股收益為$1.18，低於分析師一致預期的$1.52，差額為 ($0.34)。該公司季度收入為 114.4 億美元，而分析師預期為 120.9 億美元。禮來公司的股本回報率為 71.08%，淨利潤率為 20.48%。該公司的季度收入較去年同期增長了 20.4%。去年同期，該公司每股收益為$0.10。賣方分析師預測，禮來公司在當前財政年度的每股收益將達到$13.18。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>禮來公司增加分紅</h2>
</div><ul>
<li>Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon</li>
</ul>
<div class="lb-trans"><ul>
<li>諾和諾德：GLP-1 銷售的新動力即將到來</li>
</ul>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a yield of 0.78%. Eli Lilly and Company's dividend payout ratio is presently 64.86%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度分紅，將於 3 月 10 日支付。2 月 14 日的股東將獲得每股$1.50 的分紅。這比禮來公司之前的季度分紅$1.30 有所增加。除息日為 2 月 14 日。這代表着每年$6.00 的分紅和 0.78% 的收益率。禮來公司的分紅支付比率目前為 64.86%。</p>
</div><p>Eli Lilly and Company declared that its Board of Directors has initiated a share repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.</p>
<div class="lb-trans"><p>禮來公司宣佈其董事會已於 12 月 9 日啓動了一項股票回購計劃，允許公司回購 150 億美元的股票。該回購授權允許公司通過公開市場購買最多 2% 的股票。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
</div><h2>Insider Transactions at Eli Lilly and Company</h2>
<div class="lb-trans"><h2>禮來公司的內部交易</h2>
</div><p>In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他禮來公司的新聞中，首席會計官 Donald A. Zakrowski 在 11 月 8 日的交易中出售了 900 股禮來公司的股票。該股票以平均價格$803.38 出售，總交易額為$723,042.00。交易完成後，首席會計官現在持有該公司 5,480 股股票，價值約$4,402,522.40。此次交易使其持股減少了 14.11%。該交易已在向證券交易委員會提交的文件中披露，文件可通過 SEC 網站訪問。目前，內部人士持有該股票的 0.13%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of LLY. International Assets Investment Management LLC grew its stake in shares of Eli Lilly and Company by 87,091.7% in the 3rd quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock worth $11,041,631,000 after acquiring an additional 12,448,888 shares in the last quarter. Pathway Financial Advisers LLC increased its stake in Eli Lilly and Company by 92,759.9% in the 3rd quarter. Pathway Financial Advisers LLC now owns 1,022,388 shares of the company's stock valued at $905,774,000 after buying an additional 1,021,287 shares during the last quarter. Wulff Hansen &amp; CO. lifted its position in shares of Eli Lilly and Company by 90,438.0% during the 2nd quarter. Wulff Hansen &amp; CO. now owns 937,068 shares of the company's stock worth $848,403,000 after buying an additional 936,033 shares in the last quarter. Integrated Investment Consultants LLC boosted its stake in shares of Eli Lilly and Company by 37,140.7% in the 3rd quarter. Integrated Investment Consultants LLC now owns 694,167 shares of the company's stock worth $614,990,000 after buying an additional 692,303 shares during the last quarter. Finally, Comerica Bank grew its holdings in shares of Eli Lilly and Company by 71.6% in the second quarter. Comerica Bank now owns 1,512,983 shares of the company's stock valued at $1,369,825,000 after acquiring an additional 631,312 shares in the last quarter. Institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些大型投資者調整了他們在禮來公司的持股。國際資產投資管理公司在第三季度將其在禮來公司的股份增加了 87,091.7%。國際資產投資管理公司現在擁有 12,463,182 股該公司的股票，價值 11,041,631,000 美元，此前在上個季度又增持了 12,448,888 股。Pathway Financial Advisers LLC 在第三季度將其在禮來公司的股份增加了 92,759.9%。Pathway Financial Advisers LLC 現在擁有 1,022,388 股該公司的股票，價值 905,774,000 美元，此前在上個季度又增持了 1,021,287 股。Wulff Hansen &amp; CO.在第二季度將其在禮來公司的股份增加了 90,438.0%。Wulff Hansen &amp; CO.現在擁有 937,068 股該公司的股票，價值 848,403,000 美元，此前在上個季度又增持了 936,033 股。Integrated Investment Consultants LLC 在第三季度將其在禮來公司的股份增加了 37,140.7%。Integrated Investment Consultants LLC 現在擁有 694,167 股該公司的股票，價值 614,990,000 美元，此前在上個季度又增持了 692,303 股。最後，Comerica Bank 在第二季度將其在禮來公司的持股增加了 71.6%。Comerica Bank 現在擁有 1,512,983 股該公司的股票，價值 1,369,825,000 美元，此前在上個季度又增持了 631,312 股。機構投資者持有該公司 82.53% 的股份。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>禮來公司公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；以及 Zepbound 用於肥胖。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>What is MarketRank™? How to Use it</li>
<li>3 Legacy Tech Companies Reemerging as AI Leaders</li>
<li>What is a support level?</li>
<li>Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比禮來公司更好的股票</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>3 家傳統科技公司重新崛起為 AI 領導者</li>
<li>什麼是支撐位？</li>
<li>分析師最喜歡的網絡安全股票：3 個頂級推薦</li>
<li>3 只提供優厚股息收益的天然氣股票</li>
<li>分析師看好：3 家科技巨頭的目標價被上調</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><p>→ We recommended Palantir in 2021, now we’re recommending this... (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 我們在 2021 年推薦了 Palantir，現在我們推薦這個...（來自 Behind the Markets）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTExNQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=11115&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Eli Lilly and Company right now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮禮來公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而禮來公司並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然禮來公司目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

禮來公司（NYSE:LLY）股價上漲 1% - 現在是買入的好時機嗎？